4D Pharma PLC
LBPS
LBPS was delisted on the 24th of June, 2022.
10 hedge funds and large institutions have $2.03M invested in 4D Pharma PLC in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
43% more funds holding
Funds holding: 7 → 10 (+3)
9% more capital invested
Capital invested by funds: $1.87M → $2.03M (+$159K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$132K |
| 2 |
Morgan Stanley
New York
|
+$94.4K |
| 3 |
Capstone Investment Advisors
New York
|
+$63.5K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$49.5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$35.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG
StoneX Group
New York
|
-$86.6K |
LBPS Hedge Fund Activity: Q1 2022 in Review
10 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in 4D Pharma PLC (LBPS) for Q1 2022, worth a combined $2.03M — up 8.5% from $1.87M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new LBPS positions and 1 closed out — a net gain of 3 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $132K. The largest seller was StoneX Group, exiting entirely with an estimated $86.6K sold.
- 10 institutional investors held 4D Pharma PLC (LBPS) as of Q1 2022, up from 7 in Q4 2021.
- Funds reported $2.03M of 4D Pharma PLC stock for Q1 2022, up 8.5% quarter-over-quarter.
- 4 funds opened new 4D Pharma PLC positions in Q1 2022 and 1 closed out, a net change of +3 holders.
- The largest 4D Pharma PLC buyer in Q1 2022 was Citadel Advisors, an estimated $132K added.
- The largest 4D Pharma PLC seller in Q1 2022 was StoneX Group, an estimated $86.6K sold.
Based on aggregated 13F filings for Q1 2022.